22:29 , Sep 21, 2018 |  BioCentury  |  Emerging Company Profile

Aprinoia tackles tau

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates. “We are going to...
22:07 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018...
23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD); progressive supranuclear palsy (PSP) Patient sample and fly studies suggest PIWIL1 overexpression or inhibiting viral DNA polymerases could help treat AD, PSP and other tauopathies. In postmortem cortex and cerebellum samples...
20:23 , Feb 23, 2018 |  BC Week In Review  |  Company News

Voyager, AbbVie to develop anti-tau gene therapies

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) partnered with AbbVie Inc. (NYSE:ABBV) to develop gene therapies to express microtubule-associated protein tau (tau; MAPT; FTDP-17) antibodies to treat Alzheimer's disease and other tauopathies. Using Voyager's adeno-associated...
22:35 , Feb 20, 2018 |  BC Extra  |  Company News

Voyager, AbbVie partner for AD gene therapies

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) jumped $4.30 (22%) to $23.66 on Tuesday after partnering with AbbVie Inc. (NYSE:ABBV) to develop gene therapies to express microtubule-associated protein tau (tau; MAPT; FTDP-17) antibodies to treat...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
23:53 , Jul 25, 2017 |  BC Extra  |  Company News

Spinraza sales drive Biogen's guidance bump

Biogen Inc. (NASDAQ:BIIB) reported 2Q17 earnings, raised its full-year revenue guidance for 2017 and laid out a five-part growth strategy that emphasizes multiple sclerosis, spinal muscular atrophy (SMA) and neuroscience. The company said faster-than-expected uptake...
16:33 , Apr 14, 2017 |  BC Week In Review  |  Company News

BMS, Biogen deal

Bristol-Myers granted Biogen exclusive rights to BMS-986168 . The mAb targeting microtubule-associated protein tau (tau; MAPT; FTDP-17) has completed a Phase Ib trial to treat progressive supranuclear palsy (PSP). Biogen said it intends to start...
19:32 , Apr 13, 2017 |  BC Extra  |  Company News

BMS out-licenses programs to Biogen, Roche

Bristol-Myers Squibb Co. (NYSE:BMY) said Thursday it out-licensed a pair of programs to Biogen Inc. (NASDAQ:BIIB) and Roche (SIX:ROG; OTCQX:RHHBY). Spokesperson Chrissy Trank told BioCentury the deals end BMS's clinical development of therapies for genetically...
22:14 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

ABBV-8E12: Ph II started

AbbVie began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate IV ABBV-8E12 in about 180 patients. AbbVie has exclusive, worldwide rights to develop and commercialize the product from C2N (see BioCentury, April 13, 2015...